Last updated: March 10, 2026
What is HADLIMA (CF) Pushtouch?
HADLIMA (CF) Pushtouch is a biosimilar of Humira (adalimumab), used primarily in autoimmune conditions such as rheumatoid arthritis, Crohn’s disease, and psoriasis. Its immediate market entry aims to capture the existing approved indications of the reference product.
Current Market Landscape
Market Size and Growth
- The global autoimmune biologics market was valued at approximately USD 40 billion in 2022.
- It is expected to grow at a CAGR of 8–10% through 2030, driven by increasing prevalence of autoimmune diseases and biosimilar penetration.
- The biologic segment dominates, comprising roughly 70% of the total autoimmune therapies market.
Key Competitors
| Product |
Developer |
Market Share (2022) |
Approved Indications |
Launch Date |
| Humira (adalimumab) |
AbbVie |
40% |
10+ |
2003 |
| Amjevita |
Amgen |
- |
6 indications |
2016 |
| Imraldi |
Samsung Bioepis |
- |
5 indications |
2017 |
| Hadlima |
Samsung Bioepis |
Pending |
Similar to Humira |
Expected 2024 |
Regulatory Status
- HADLIMA (CF) Pushtouch received FDA approval in late 2022.
- European Medicines Agency (EMA) approved in Q2 2023.
- Launch in the U.S. expected in Q2 2024.
Pricing Dynamics
- Raw Humira prices have ranged from USD 5,000 to USD 7,500 per year per patient in the U.S.
- Biosimilar prices typically 15–30% lower; initially priced around USD 4,000 to USD 5,000 per year.
Price Projections
Pricing Trends
- Biosimiars typically undercut originator prices by 20–30% at launch.
- Price erosion occurs over 2–3 years due to market penetration and generic competition.
- Industry estimates project biosimilar prices for HADLIMA to average USD 3,500–USD 4,500 annually per patient within the first 2 years of launch.
Market Penetration and Revenue Estimates
| Year |
Estimated Price (USD) |
Projected Patients (millions) |
Revenue (USD billions) |
| 2024 |
4,000 |
0.5 |
2.0 |
| 2025 |
3,750 |
0.75 |
2.8 |
| 2026 |
3,500 |
1.0 |
3.5 |
- These projections assume gradual market uptake, reaching approximately 20% of the Humira market share within five years.
Regional Variations
- United States: Higher pricing due to reimbursement structures, potential for USD 4,000–USD 5,000 per patient annually.
- Europe: Slightly lower prices; biosimilar adoption has been higher historically, possibly leading to price points around USD 3,000–USD 4,000.
Market Entry Factors
- Payers and insurance coverage significantly influence uptake.
- Physician prescriber confidence in biosimilars influences early adoption.
- Patent expiration of Humira in key markets, notably the U.S., in 2023–2024.
Risks and Challenges
- Patent litigations delaying market entry.
- Preferential prescribing for original biologics.
- Market resistance due to perceived efficacy differences.
Policy Impact
- Some countries enforce biosimilar substitution policies, increasing uptake.
- Price negotiation strategies or reference pricing policies may constrain prices.
Implications for Stakeholders
- Investment in biosimilar portfolio diversification can generate early revenue streams.
- Pharmaceutical firms entering the biosimilar market must manage pricing to balance volume with margin erosion.
- Governments and payers will influence price ceilings through regulation and reimbursement policies.
Key Takeaways
- HADLIMA (CF) Pushtouch aims for peak revenue of approximately USD 3.5 billion annually within five years.
- Initial prices projected at USD 4,000–USD 5,000 per patient annually, with downward pressure over time.
- Market share will depend heavily on regulatory approval timing, payer agreements, and physician adoption.
- Competition from other biosimilars like Amjevita and Imraldi will influence pricing and market penetration.
- Regional differences in price and uptake hinge on regulatory environments and market maturity.
FAQs
1. When is HADLIMA (CF) Pushtouch expected to launch?
Expected in Q2 2024 in the U.S. following regulatory approval.
2. How will the price of HADLIMA compare to the originator Humira?
Initially 20–30% lower, around USD 4,000–USD 5,000 annually, decreasing as market penetration increases.
3. What challenges could delay market penetration?
Patent litigations, prescriber resistance, reimbursement hurdles, and regulatory delays.
4. What are the main markets for HADLIMA?
United States, Europe, and other high-income countries with established biosimilar policies.
5. How will biosimilar competition affect long-term pricing?
Prices are likely to decline steadily as multiple biosimilars enter and competition intensifies.
References
[1] IQVIA. (2022). Biologics Market Report.
[2] EvaluatePharma. (2023). Global Biosimilars Market Size & Trends.
[3] FDA. (2022). Biosimilar Product Approvals.
[4] EMA. (2023). Regulatory Approvals for Biosimilars.
[5] CMS. (2023). Reimbursement and Pricing for Biosimilars.
